Acumen Pharmaceuticals is a dedicated team of experienced professionals focused on developing targeted therapies for Alzheimer's disease. Their most advanced candidate, ACU193, is a monoclonal antibody designed to selectively target toxic soluble amyloid beta oligomers for the treatment of early Alzheimer's disease, with the potential for disease-modifying benefits and symptomatic relief.
With a keenness and depth of perception, Acumen is building upon decades of research to drive the field forward and achieve better outcomes for Alzheimer's patients, aiming to help them hold on to their precious moments and create new ones.
Generated from the website